argenx SE (EBR:ARGX)
691.20
+20.40 (3.04%)
May 11, 2026, 5:35 PM CET
argenx SE Revenue
argenx SE had revenue of $1.31B USD in the quarter ending March 31, 2026, with 62.70% growth. This brings the company's revenue in the last twelve months to $4.75B, up 79.62% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$4.75B
Revenue Growth
+79.62%
P/S Ratio
10.45
Revenue / Employee
$2.55M
Employees
1,863
Market Cap
42.98B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.32M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 8.83M |
| Onward Medical | 5.41M |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| Oxurion NV | 2.00K |
| BioSenic | -2.39M |
argenx SE News
- 7 hours ago - Argenx price target raised to $1,016 from $1,013 at BofA - TheFly
- 11 hours ago - Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients - Nasdaq
- 2 days ago - argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis - GuruFocus
- 2 days ago - Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use - GuruFocus
- 2 days ago - Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo - TheFly
- 2 days ago - argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - GlobeNewsWire
- 3 days ago - ARGX Maintained by Guggenheim -- Price Target Raised to $1135 - GuruFocus
- 3 days ago - ARGX Maintained by Wells Fargo -- Price Target Raised to $1260 - GuruFocus